Skip to main content Help with accessibility Skip to main navigation

All Guidance

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - March - 2018
BNF chapter: Respiratory system
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - June - 2022
BNF chapter: Endocrine system

Advanced hormone-dependent prostate cancer with spinal metastases - to be read in conjunction with the SPC

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - January - 2018
BNF chapter: Central nervous system

To be read in conjunction with the SPC , NICE TA 217 and NICE CG42

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - April - 2018

Denosumab 60mg injection - Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture and treatment of bone loss
associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - February - 2018

Denosumab as a second-line treatment option for the prevention of Osteoporotic Fragility Fractures

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - September - 2016
BNF chapter: Central nervous system

The Lancashire Medicines Management Group does not recommend the prescribing of e-Cigarettes

Adopted
Adopted
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Date Posted: 01 - January - 2018
BNF chapter: Genito-urinary system

This guidance includes a flow chart indicating a step-wise approach to the management of ED, with additional treatment notes that have been developed to guide prescribers

 

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - December - 2018
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2017
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 16 - November - 2022

Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).

Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Adopted
Date Posted: 01 - December - 2018
BNF chapter: Musculoskeletal system
**This Guideline is currently under review. For further information please click here**
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - October - 2018
BNF chapter: Central nervous system
**This Guideline is currently under review. For further information please click here**

Formerly the 'North West Headache Management Guideline for Adults'

Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 13 - May - 2022
BNF chapter: Cardiovascular system
Adopted
Adopted
Pending
Adopted
Adopted
Pending
Adopted
Pending
Date Posted: 14 - September - 2022
BNF chapter: Central nervous system

To be read in conjunction with the LSCMMG guideline ‘Assessing suitability of strong opioid use’

 

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - May - 2017
BNF chapter: Endocrine system

The purpose of this guideline is to assist primary care practitioners to advise patients of the appropriate monitoring regimen for their clinical condition and diabetes type and to ensure appropriate volumes of testing strips are supplied.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - September - 2022

For Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight in adults Information for prescribers - to be read in conjunction with the SPC

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Pending
Date Posted: 20 - January - 2022
BNF chapter: Cardiovascular system

Please refer to the LSCMMG inclisiran medicines entry for further information on use within Lancashire and South Cumbria - RAG rated 'Green (Restricted)'.

Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 01 - June - 2016
BNF chapter: Endocrine system

This information sheet has been produced to summarise key information about insulin Toujeo for those providing care for patients on this insulin, including on-going prescribing, supply or administration. It is not specifically intended for diabetes specialists who are responsible for initiation and switching to/from insulin Toujeo®. Specialists are advised to refer to the SPC and local protocols for further information.

Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Adopted
Date Posted: 14 - June - 2022
BNF chapter: Cardiovascular system
For the symptomatic treatment of chronic stable angina or chronic heart failure Information for prescribers - to be read in conjunction with the SPC
Not adopted
Adopted
Adopted
Not adopted
Adopted
Adopted
Pending
Pending
Date Posted: 18 - February - 2020
The Lancashire and South Cumbria Self-Care and Access to OTC Medicines – Template policy has been developed for use by care homes in Lancashire and South Cumbria. The policy must be reviewed by each care home for suitability and finalised prior to use.
This policy MUST be read in conjunction with the local or care home medicines policy